Prophylactic and therapeutic vaccination
There is a globally unmet and critical need to prevent and treat infectious disease and cancer.
We support patients and healthcare providers by developing prophylactic and therapeutic
immunotherapies across a diverse pipeline, covering:
Thanks to our highly effective proprietary technology platform,
we have several investigational therapies already progressing through clinical trials.
NEWS
Lenti-COVID, an effective and innovative strategy for a Covid-19 intranasal vaccine
A clinical phase still needs to be initiated to confirm the innocuousness and effectiveness of this approach in human...
L’institut Pasteur prépare-t-il un vaccin qui protège le cerveau ?
Roselyne Dubois répond à vos questions sur BFMTV.
...
Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice
Results of the joint Pasteur-TheraVectys laboratory’s work on their Covid-19 vaccine candidate based on a lenti...
Lentiviral vectors: the key to cancer treatments that CAR T-cell therapy cannot reach?
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating…
...
Using Lentiviral Vectors to Advance the Development of Therapeutic Vaccines
Traditionally, vaccination has been used as a preventative strategy, aimed at curbing the impact of a wide range of i...
Better Outfitted and Screened Viral Vectors Are Safer and More Effective
Viruses have been evolving for millions of years, improving their ability to transfer genetic material to the hosts t...
Lenti-Covid: robust answer addressing long-term immunity and emerging variants
“Neutralizing antibodies present in blood only contribute partially to protection.
...
L’interview «Savoir comprendre» : Pr Pierre Charneau
Pr Pierre Charneau, virologue et directeur du laboratoire de vaccinologie commun Pasteur-Theravectys
...
Covid-19 : comment la lutte contre les variants pourrait modifier les stratégies vaccinales
L’apparition de nouvelles mutations du virus contraint les laboratoires à adapter leurs vaccins…
...
TheraVectys Announces $20M Funding Round
Funding to drive Phase 1 and 1-2 Clinical Trials for COVID-19, HPV induced cancers and HBV Vaccine Candidates PHILADE...
Theravectys lève 16,5 millions d’Euros pour lancer les essais cliniques de ses vaccins
La biotech française Theravectys, pionnière mondiale de la technologie des vecteurs lentiviraux, a annoncé le bouc...
Vaccin et Covid-19 : et si la solution venait d’un spray nasal ?
L’Institut Pasteur de Lille a entamé des travaux de recherche pour développer un vaccin nasal…
...